Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Featured Clinical Focus
AMLBiomarker-Driven Lung CancerBone Marrow & SCTBTK Inhibitors: In-FocusCAR T-Cell TherapyChronic Lymphocytic LeukemiaEGFR-Positive Lung CancerEndometrial CancerFollicular LymphomaHCCLung CancerMantle Cell LymphomaMPNsMultiple MyelomaRenal Cell CarcinomaSmall Cell Lung CancerThyroid Cancers
Clinical Focus
View MoreBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancersGynecologic CancersHead & Neck CancersHematologyLeukemiasLung CancerLymphomasMelanomaSarcomaSkin CancersThyroid Cancers
NEWS
All NewsClinical FocusSpecial Reports
CONFERENCES
Conference CoverageConference Listing
MEDIA
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPodcastsPrecision Medicine
PUBLICATIONS
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
RESOURCES
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
eNewsletter
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Advertisement
Featured Clinical Focus
  • AML
  • Biomarker-Driven Lung Cancer
  • Bone Marrow & SCT
  • BTK Inhibitors: In-Focus
  • CAR T-Cell Therapy
  • Chronic Lymphocytic Leukemia
  • EGFR-Positive Lung Cancer
  • Endometrial Cancer
  • Follicular Lymphoma
  • HCC
  • Lung Cancer
  • Mantle Cell Lymphoma
  • MPNs
  • Multiple Myeloma
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer
  • Thyroid Cancers
Clinical FocusSee All >
  • Brain Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Hematology
  • Leukemias
  • Lung Cancer
  • Lymphomas
  • Melanoma
  • Sarcoma
  • Skin Cancers
  • Thyroid Cancers
baltimore conference logo
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

A 61-Year-Old Woman With Hepatocellular Carcinoma

Pierre Gholam, MD, reviews significant clinical trial data and treatment options for the management of unresectable HCC.

EP. 1: 61-Year-Old Female With Unresectable HCC

July 28th 2021

Pierre Gholam, MD, presents the case of a 61-year-old woman with hepatocellular carcinoma (HCC).

EP. 2: Unresectable HCC: Case Prognosis and Impressions

July 28th 2021

Dr Gholam, MD, provides expert analysis on the prognosis and treatment of a patient with unresectable HCC.

EP. 3: First-Line Treatment in Unresectable HCC

July 28th 2021

An expert in the treatment of HCC comments on first-line therapeutic options for patients with previously untreated, advanced HCC.

EP. 4: REFLECT Trial: Study Design and Key Data

July 28th 2021

Dr Gholam reviews the study design and key data from the phase 3 REFLECT trial.

EP. 5: IMbrave 150 Trial: Safety and Efficacy Data

July 28th 2021

Gastroenterology expert, Dr Pierre Gholam, discusses the efficacy and safety data from the phase 3 IMbrave150 trial.

EP. 6: Unresectable HCC: Unmet Treatment Needs

July 28th 2021

Pierre Gholam, MD, discusses future directions and novel therapeutic agents for the treatment of unresectable HCC.

EP. 7: Unresectable HCC: Key Treatment Considerations

July 28th 2021

A key opinion leader shares clinical practice pearls for the treatment of patients with unresectable HCC. 

Advertisement
Advertisement